There has been a further update to the list today.
Several movements to baseline commissioning.
🔔But also noted that #Kadcyla (#Tratsuzumab Emtansine) no longer specifies a LVEF threshold on the blueteq
Nivolumab- Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untr...
https://updates.chemo.org.uk/CDF_Forms/NIV25.html
🚨 Correction of Nice Approved Indication
Belantamab mafodotin with pomalidomide and...- Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patie...
https://updates.chemo.org.uk/CDF_Forms/BELA2.html
🚨 Spelling of drug name corrected to Belanta...
Belantamab mafodotin in combination with b...- Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma i...
https://updates.chemo.org.uk/CDF_Forms/BELA1.html
🚨 Spelling of drug name corrected to Belanta...
Pomalidomide- Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
https://updates.chemo.org.uk/CDF_Forms/POM1.html
🚨 Treatment criterion (#6) updated
NA- NA
https://updates.chemo.org.uk/CDF_Forms/NIV9.html
🚨 Treatment criterion (#8) updated
Bevacizumab with FIRST LINE fluoropyrimidi...- For metastatic or locally advanced and inoperable colorectal cancer
https://updates.chemo.org.uk/CDF_Forms/BEV11.html
🚨 Treatment criterion (#4) updated
Abiraterone In combination with androgen d...- For the treatment of newly diagnosed high risk metastatic hormone-sensitive prostate cancer
https://updates.chemo.org.uk/CDF_Forms/ABI4.html
🚨 Treatment criterion (#6) updated
Nivolumab- Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untr...
https://updates.chemo.org.uk/CDF_Forms/NIV25.html
🚨 Date moving into routine commissioning upd...
Lorlatinib monotherapy- Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with a...
https://updates.chemo.org.uk/CDF_Forms/LOR2.html
🚨 Moved into routine commissioning - section...
Durvalumab- Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following plati...
https://updates.chemo.org.uk/CDF_Forms/DUR7.html
🚨 Moved into routine commissioning - section...
Avelumab in combination with axitinib- For use in treatment-naïve patients with advanced, favourable risk, renal cell carcinoma
https://updates.chemo.org.uk/CDF_Forms/AVE3.html
🚨 Moved into routine commissioning - section...
Durvalumab with gemcitabine and cisplatin- For neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer
https://updates.chemo.org.uk/CDF_Forms/DUR8.html
🚨 Recommended for routine commissioning, rec...